T-cell responses at baseline and during therapy with peginterferon-α and ribavirin are not associated with outcome in chronic hepatitis C infected patients
Background: Since the association between hepatitis C virus (HCV)-specific T-cell responses both pre-treatment and during interferon-α based therapy and viral clearance is unresolved, a combined analysis of distinctive T-cell characteristics (proliferation and interferon-γ production) is important to clarify this issue. Methods: Peripheral blood mononuclear cells (PBMC) collected in 22 chronic HCV infected patients at pre-treatment and at week 4 during pegIFN-α/ribavirin therapy, were stimulated with overlapping peptide pools in a [3H]-thymidine assay, an interferon-γ-ELISA, and a sensitive 12-day T-cell expansion assay. Results: Compared to the [3H]-thymidine proliferation and interferon-γ secretion assays, the 12-day T-cell expansion assay was more sensitive in detecting T-cell responses. No significant association was demonstrated between pre-treatment HCV-specific CD4+ or CD8+ T-cell responses and either a sustained virological response (SVR) or a rapid virological response (RVR). However, a skewing of individual responses towards the non-structural antigens was observed. During pegIFN-α/ribavirin therapy, HCV-specific CD4+ and CD8+ T-cells declined similarly in both SVR/RVR and non-SVR/non-RVR patients. Conclusion: No correlation was found between the magnitude of pre-treatment HCV-specific T-cell responses and the outcome of pegIFN-α/ribavirin therapy in terms of SVR and RVR. Moreover, the magnitude of HCV-specific T-cell responses declined in all patients early during treatment.
|Keywords||CD4+ T-cell, CD8+ T-cell, Hepatitis C virus, Peginterferon-α, Ribavirin|
|Persistent URL||dx.doi.org/10.1016/j.antiviral.2010.06.002, hdl.handle.net/1765/20077|
Arends, J.E, Claassen, M.A.A, van den Berg, C.H.S.B, Nanlohy, N.M, van Erpecum, K.J, Baak, B.C, … van Baarle, D. (2010). T-cell responses at baseline and during therapy with peginterferon-α and ribavirin are not associated with outcome in chronic hepatitis C infected patients. Antiviral Research, 87(3), 353–360. doi:10.1016/j.antiviral.2010.06.002